Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Beebe Medical Center
mi
from
Lewes, DE
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Orlando
mi
from
Orlando, FL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Memorial Health University Medical Center
mi
from
Savannah, GA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Sudarshan K Sharma MD Limited-Gynecologic Oncology
mi
from
Hinsdale, IL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Sudarshan K Sharma MD Limited-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Baystate Medical Center
mi
from
Springfield, MA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Lake Huron Medical Center
mi
from
Port Huron, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Lake Huron Medical Center
mi
from
Port Huron, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Cox Medical Center South
mi
from
Springfield, MO
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital
mi
from
Columbus, OH
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
mi
from
Mentor, OH
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
mi
from
Mentor, OH
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Abington Memorial Hospital
mi
from
Abington, PA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
West Penn Hospital
mi
from
Pittsburgh, PA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
West Penn Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Women and Infants Hospital
mi
from
Providence, RI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Baylor All Saints Medical Center at Fort Worth
mi
from
Fort Worth, TX
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Baylor All Saints Medical Center at Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Lyndon Baines Johnson General Hospital
mi
from
Houston, TX
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Lyndon Baines Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Catherine Frenette
mi
from
La Jolla, CA
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Catherine Frenette
mi
from
La Jolla, CA
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Drexel University
mi
from
Philadelphia, PA
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Drexel University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University Hospital
mi
from
Baltimore, MD
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Nebraska Hem-Onc
mi
from
Lincoln, NE
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Nebraska Hem-Onc
mi
from
Lincoln, NE
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Pacific Medical Center
mi
from
San Francisco, CA
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Piedmont Research Institute
mi
from
Atlanta, GA
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Piedmont Research Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Southern California Research Center
mi
from
Coronado, CA
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Southern California Research Center
mi
from
Coronado, CA
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
University of California at San Diego Moores Cancer Center
mi
from
San Diego, CA
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
University of California at San Diego Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Univ of Hawaii
mi
from
Honolulu, HI
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Univ of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
University of Maryland, Greenbaum Cancer Center
mi
from
Baltimore, MD
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
University of Maryland, Greenbaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials